Abstract
I am grateful to accept the invitation to provide this commentary on the recently published article entitled “Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomized, multicenter, open-label phase 3 trial” (1). This important trial adds to the salvage radiotherapy literature which historically has been largely populated with retrospective analyses. The GETUG-AFU 16 trial observed improved progression-free survival when 6 months of goserelin was added to radiotherapy. In this short note I will provide a critical appraisal of the GETUG study, briefly describe another trial of salvage radiotherapy and androgen suppression (RTOG/NRG Oncology 96-01) and at the end describe how I incorporate the findings of each of these studies into my practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
